Evidence map›Paper›PMID 38397263›Full record

ArticleChildren (Basel, Switzerland)2024

Research on the Clinical Practical Use of Pivoxil-Conjugated Antibodies and the Risk of Carnitine Deficiency Using Real-World Data.

Kaho Suzuki-Yoshida, Kosuke Nakano, Masayoshi Nakakuni, Naoko Deguchi, Seiji Mitsui, Shinji Kobayashi, Akimasa Yamatani, Miki Akabane

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Children (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kaho Suzuki-YoshidaGraduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo 204-0004, Japan.
Kosuke NakanoClinical Research Center, National Center for Child Health and Development, Tokyo 157-8535, Japan.
Masayoshi NakakuniClinical Research Center, National Center for Child Health and Development, Tokyo 157-8535, Japan.
Naoko DeguchiClinical Research Center, National Center for Child Health and Development, Tokyo 157-8535, Japan.
Seiji MitsuiClinical Research Center, National Center for Child Health and Development, Tokyo 157-8535, Japan.
Shinji KobayashiNature Insight Co., Ltd., Tokyo 101-0021, Japan.
Akimasa YamataniGraduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo 204-0004, Japan.
Miki AkabaneGraduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo 204-0004, Japan.
National Center For Child Health and Development · JPMeiji Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Japan, pivoxil-conjugated antibodies (PVs) are commonly used to treat infections. However, carnitine deficiency is a known adverse drug reaction associated with PV treatment. This study aimed to research the practical use of PV and assess the risk of carnitine deficiency in patients receiving PV compared to their amoxicillin (AM)-treated counterparts. The Pediatric Medical Information Collection System (P-MICS) served as the data source for this study. The study cohort comprised patients aged 0-15 years prescribed PV between April 2016 and March 2021. Data on the actual PV prescriptions were extracted for each patient. To evaluate the risk of carnitine deficiency, adverse events (AEs) were defined as carnitine deficiency and its associated symptoms. Propensity score matching was employed to compare the AE incidence between the PV and AM groups. The number of cases of PV prescriptions decreased year-on-year between 2016 and 2021, and >80% of prescriptions were dispensed in the clinic. The propensity score matching analysis demonstrated no statistically significant difference in the incidence of carnitine deficiency and its associated symptoms between the PV and AM groups. Our findings suggest that the risk of carnitine deficiency in children treated with PV is not significantly higher than that associated with other antibiotics.

Indexed as

carnitine deficiencychildrenpivoxil-conjugated antibodiesreal-world data

Identifiers

PMID38397263
PMCPMC10887142
OpenAlexW4391223460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.